MapLight Therapeutics

(NASDAQ) MPLT

Current Price$37.81

Market Cap$1.59B

Since IPO (2025)+103%

5 YearN/A

1 YearN/A

1 Month+37%

MapLight Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 37.22	2026-07-16

MapLight Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-6.48%	USD 39.80	2026-07-09
1 month	+37.04%	USD 27.16	2026-06-16
3 month	+23.86%	USD 30.05	2026-04-17
Year to date	+111.9%	USD 17.57	2025-12-31
Since inception	+102.94%	USD 18.34	2025-10-27

MapLight Therapeutics Financials at a Glance

Market Cap

$1.59B

Revenue (TTM)

$0.00

Net Income (TTM)

-$199.48M

EPS (TTM)

-$4.52

P/E Ratio

-8.24

Dividend

$0.00

Beta (Volatility)

1.99 (High)

Dividend

$0.00

Beta (Volatility)

1.99 (High)

Price

$37.81

Volume

17,343

Open

$37.15

Price

$37.81

Volume

17,343

Open

$37.15

Previous Close

$37.22

Daily Range

$36.25 - $38.43

52-Week Range

$12.24 - $40.43

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

1.99 (High)

Price

$37.81

Volume

17,343

Open

$37.15

Previous Close

$37.22

Daily Range

$36.25 - $38.43

52-Week Range

$12.24 - $40.43

Estimated Earnings Date

Aug 13, 2026

MPLT News

MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?

Sarah SidlowMay 15, 2026

This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April

Sarah SidlowMay 4, 2026

What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data

Jonathan PoncianoApr 22, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MapLight Therapeutics

MapLight develops medicines for people with brain disorders like schizophrenia and autism. Its main products aim to improve thinking, mood, and movement. These treatments help patients manage symptoms that disrupt daily life.

Brainy Business: Products and Services

ML-007C-MA (Lead Candidate): A medicine in testing for schizophrenia and psychosis in Alzheimer’s disease; targets brain receptors to reduce symptoms. (0% of revenue; pre-commercial)
ML-004: A treatment in trials for social and behavioral issues in autism spectrum disorder. (0% of revenue; pre-commercial)
ML-009: An early-stage drug for hyperactivity and agitation-related disorders; not yet in human trials. (0% of revenue; pre-commercial)
ML-021: A preclinical therapy for movement problems in Parkinson’s disease. (0% of revenue; pre-commercial)
Discovery Platform: Uses advanced lab tools to find new drug targets in brain circuits. (0% of revenue; supports pipeline)

Growth Spurts: Expansion Moves

Acquired M1/M4 agonist molecules and patents from NeuroSolis in 2025.
Signed technology agreement with Stellaromics for transcriptomic devices in 2023.
Launched Phase 2 trials for schizophrenia and Alzheimer’s psychosis in 2025–2026.
Completed enrollment for autism trial (IRIS) in 2026.
Raised $469.8 million through IPO, private placements, and issuance of Series D redeemable convertible preferred stock in 2025.

What Makes MapLight Stand Out

MapLight focuses on brain circuit-based drug discovery, aiming for targeted treatments. Its platform combines genetic and imaging tools to pinpoint disease pathways. The company holds global rights to its pipeline and manages all development in-house.

Five Things You Need to Know

Revenue was $0 in Q3 2025, unchanged from Q3 2024.
Net loss was $31 million in Q3 2025, down 50.8% year-over-year.
Cash, cash equivalents, and investments totaled $453.1 million at December 31, 2025.
R&D expenses rose to $138.3 million in 2025, up from $68.5 million in 2024.
Market cap was $14.32 million as of March 2026, with 42.4 million shares outstanding.

Bottom Line

MapLight remains focused on developing new brain disorder treatments. The company invests heavily in research, with no product sales to date.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

133

CEO

Christopher A. Kroeger, MD, MBA

Website

www.maplightrx.com

Headquarters

Redwood City, CA 94063, US

MPLT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-69.06%

Return on Capital

-36.43%

Return on Assets

-47.63%

Earnings Yield

-12.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.59B

Shares Outstanding

42.62M

Volume

17.34K

Avg. Volume

406.69K

Financials (TTM)

Gross Profit

-$574.00K

Operating Income

-$210.04M

EBITDA

-$198.91M

Operating Cash Flow

-$163.77M

Capital Expenditure

-$497.00K

Free Cash Flow

-$164.26M

Cash & ST Invst.

$310.11M

Total Debt

$5.59M

MapLight Therapeutics Performance Analysis

MapLight Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

MapLight Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

MapLight Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.72	N/A
2023	2023-12-31	USD -1.34	85.6%
2024	2024-12-31	USD -1.87	39.3%
2025	2025-12-31	USD -3.66	95.5%

MapLight Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-33.3%
Q3	2025-09-30	1.4%
Q4	2025-12-31	-154.9%
Q1	2026-03-31	26.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$162.00K

+2.4%

Gross Margin

0.00%

N/A

Market Cap

$1.59B

N/A

Market Cap/Employee

$11.93M

N/A

Employees

133

N/A

Net Income

-$60.67M

-171.6%

EBITDA

-$60.51M

-172.9%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$310.11M

+236.1%

Total Debt

$5.59M

-12.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.67M

-16.4%

Short Term Debt

$920.00K

+14.3%

Return on Assets

-47.63%

N/A

Return on Invested Capital

-51.93%

N/A

Free Cash Flow

-$51.20M

-100.4%

Operating Cash Flow

-$51.18M

-100.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

EDSAEdesa Biotech, Inc.

EDSAEdesa Biotech, Inc.$6.69-0.52%

PMNProMIS Neurosciences, Inc.

PMNProMIS Neurosciences, Inc.$14.76+10.98%

LPCNLipocine Inc.

LPCNLipocine Inc.$2.25-1.75%

OSRHOSR Holdings, Inc.

OSRHOSR Holdings, Inc.$0.46-5.23%

IMRNImmuron Limited

IMRNImmuron Limited$1.20+5.75%

TRAWTraws Pharma, Inc.

TRAWTraws Pharma, Inc.$0.68+2.03%

BRTXBioRestorative Therapies, Inc.

BRTXBioRestorative Therapies, Inc.$0.35-1.40%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.12-0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$69.42-0.02%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$30.23+0.10%

PATHUiPath

PATHUiPath$12.30+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$41.67+0.02%

AAPLApple

AAPLApple$330.32-0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.60-0.04%

Questions About MPLT

What is the current price of MapLight Therapeutics?

MapLight Therapeutics is trading at $37.81 per share.

What is the 52-week range for MapLight Therapeutics?

Over the past 52 weeks, MapLight Therapeutics has traded between $12.24 and $40.43.

How much debt does MapLight Therapeutics have?

As of the most recent reporting period, MapLight Therapeutics reported total debt of $5.59M.

How much cash does MapLight Therapeutics have on hand?

MapLight Therapeutics reported $55.71M in cash and cash equivalents in its most recent financial results.

What is MapLight Therapeutics’s dividend yield?

MapLight Therapeutics does not currently have a dividend yield.

MapLight Therapeutics

MapLight Therapeutics Financials at a Glance

MPLT News

MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?

This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April

What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MapLight Therapeutics

Brainy Business: Products and Services

Growth Spurts: Expansion Moves

What Makes MapLight Stand Out

Five Things You Need to Know

Bottom Line

MPLT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MapLight Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MPLT

What is the current price of MapLight Therapeutics?

What is the 52-week range for MapLight Therapeutics?

How much debt does MapLight Therapeutics have?

How much cash does MapLight Therapeutics have on hand?

What is MapLight Therapeutics’s dividend yield?

Premium Investing Services